

09/975,586

C.A.S 5-21-02

=> d ibib abs hitstr 113 1-517

L13 ANSWER 1 OF 517 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:124665 CAPLUS

DOCUMENT NUMBER: 136:275052

TITLE: Generation of an activating Zn²⁺ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle

AUTHOR(S): Loland, Claus Juul; Norregaard, Lene; Litman, Thomas; Gether, Ulrik

CORPORATE SOURCE: Division of Cellular and Molecular Physiology, Department of Medical Physiology 12.5, The Panum Institute, University of Copenhagen, Copenhagen, DK-2200, Den.

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(3), 1683-1688
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Binding of Zn²⁺ to the endogenous Zn²⁺ binding site in the human dopamine transporter leads to potent inhibition of [3H]dopamine uptake. Here we show that mutation of an intracellular tyrosine to alanine (Y335A) converts this inhibitory Zn²⁺ switch into an activating Zn²⁺ switch, allowing Zn²⁺-dependent activation of the transporter. The tyrosine is part of a conserved YXX.PHI. trafficking motif (X is any residue and .PHI. is a residue with a bulky hydrophobic group), but Y335A did not show alterations in surface targeting or protein kinase C-mediated internalization. Despite wild-type levels of surface expression, Y335A displayed a dramatic decrease in [3H]dopamine uptake velocity (V_{max}) to less than 1% of the wild type. In addn., Y335A showed up to 150-fold decreases in the apparent affinity for cocaine, mazindol, and related inhibitors whereas the apparent affinity for several substrates was increased. However, the presence of Zn²⁺ in micromolar concns. increased the V_{max} up to 24-fold and partially restored the apparent affinities. The capability of Zn²⁺ to restore transport is consistent with a reversible, constitutive shift in the distribution of conformational states in the transport cycle upon mutation of Tyr-335. We propose that this shift is caused by disruption of intramol. interactions important for stabilizing the transporter in a conformation in which extracellular substrate can bind and initiate transport, and accordingly that Tyr-335 is crit. for regulating isomerization between discrete states in the transport cycle.

IT 135500-23-1, RTI 55

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RTI 55; effect of a mutation of human dopamine transporter on inhibitor and substrate affinity)

RN 135500-23-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-iodophenyl)-8-methyl-, methyl ester, (1R,2S,3S,5S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 135416-43-2

CMF C16 H20 I N O2

CDES *

Absolute stereochemistry.


09/975,586



CM 2


CRN 87-69-4
CMF C4 H6 O6
CDES 1:R2:R*,R*

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 517 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:101699 CAPLUS
DOCUMENT NUMBER: 136:310054
TITLE: Synthesis and Biological Evaluation of 2-Substituted
3.beta.-Tolyltropane Derivatives at Dopamine,
Serotonin, and Norepinephrine Transporters
AUTHOR(S): Xu, Lifeng; Izenwasser, Sari; Katz, Jonathan L.;
Kopajtic, Theresa; Klein-Stevens, Cheryl; Zhu, Naiju;
Lomenzo, Stacey A.; Winfield, Leyte; Trudell, Mark L.
CORPORATE SOURCE: Department of Chemistry, University of New Orleans,
New Orleans, LA, 70148, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(6),
1203-1210
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of eight 2-substituted 3-tolyltropane derivs. were synthesized, and the in vitro and in vivo biol. activities as dopamine uptake inhibitors were detd. From the in vitro structure-activity data, it is apparent that a tolyl group in the 2-position, independent of the stereochem. attachment to the tropane ring system, provided compds. that exhibit high-affinity binding at the dopamine transporter (DAT). Although a slight stereochem. preference in binding affinity at the DAT was obsd. for the 2.beta.-(R)-alc. I (R = H, R1 = 4-MeC6H4) over the 2.beta.-(S)-isomer I (R = 4-MeC6H4, R1 = H), no significant differences in behavioral effects were obsd. Furthermore, despite a relatively low potency of I (R = H, R1 = 4-MeC6H4) for the inhibition of dopamine uptake compared to its affinity for the DAT, its behavioral profile did not vary significantly from cocaine. These data indicate that a behavioral characterization of compds. is a crit. feature of efforts to discover pharmacol. treatments for cocaine abuse. Also, the abs. configuration of I (R = H, R1 = 4-MeC6H4) was confirmed by x-ray crystallog.

IT 130342-81-3 187093-02-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn., dopamine, serotonin, and norepinephrine transporter binding, and structure-activity relationship of 3.beta.-tolyltropanes potentially for cocaine abuse treatment)

RN 130342-81-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(4-methylphenyl)-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187093-02-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(4-methylphenyl)-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT:

33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


09/975,586

Absolute stereochemistry. Rotation (-).



RN 50583-05-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1S,2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 516 OF 517 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1974:463837 CAPLUS
DOCUMENT NUMBER: 81:63837
TITLE: Tropane-2-carboxylates and derivatives
INVENTOR(S): Clarke, Robert L.; Daum, Sol J.
PATENT ASSIGNEE(S): Sterling Drug Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
	US 3813404	A	19740528	US 1972-306918	19721115
GI	For diagram(s), see printed CA Issue.				
AB	Tropanecarboxylates I (R = CO ₂ Me, CO ₂ CHMe ₂ , H; R ₁ = H, CO ₂ Me; R ₂ = Ph, 4-FC ₆ H ₄ , 4-MeOC ₆ H ₄ , 3-MeOC ₆ H ₄ , 3-HOC ₆ H ₄) and their salts (19 compds.) were prep'd. by Grignard reaction of R ₂ Br with (+)- and (-)-anhydroecgonine alkylesters. Thus, 0.5 mole (-)-anhydroecgonine Me ester was treated with 1.0 mole PhMgBr at -20.degree. under N to give a mixt. of I (R = CO ₂ Me, R ₁ = H, R ₂ = Ph; R = H, R ₁ = CO ₂ Me, R ₂ = Ph), which was sepd. chromatog. I (R = CO ₂ Me, R ₁ = H, R ₂ = Ph) was 16 times as active as cocaine as a stimulant in the locomotor activity test while I (R = CO ₂ Me, R ₁ = H, R ₂ = 4-FC ₆ H ₄) (II) was 64 times as active. Also II was 5 and 20 times as active as cocaine in the reserpine-induced ptosis prevention and reversal tests, resp. I (R, R ₁ = alkoxycarbonyl, R ₂ = aryl) possessed 10-20% of the local anesthetic activity of cocaine in guinea pigs.				
IT	50370-56-4P 50372-80-0P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and pharmacol. of)				

09/975,586

RN 50370-56-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50372-80-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 43021-25-6P 50370-54-2P 50370-56-4P
50370-57-5P 50370-58-6P 50372-80-0P
50372-81-1P 50372-90-2P 50372-91-3P
50372-92-4P 50372-95-7P 50372-96-8P
50373-01-8P 50373-02-9P 50763-12-7P
50798-53-3P 53898-66-1P 53898-68-3P
53898-70-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 43021-25-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, [1R-(exo,exo)]-, 1,5-naphthalenedisulfonate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 50370-56-4

CMF C16 H20 F N O2

CDES *

Absolute stereochemistry.


09/975,586



CM 2

CRN 81-04-9


CMF C10 H8 O6 S2



RN 50370-54-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50370-56-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/975,586



RN 50370-57-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50370-58-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, 1-methylethyl ester, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50372-80-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


09/975,586



RN 50372-81-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, hydrochloride, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 50372-90-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, hydrochloride, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 50372-91-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-methoxyphenyl)-8-methyl-, methyl ester, [1R-(exo,exo)]-, 1,5-naphthalenedisulfonate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 50763-12-7

09/975,586


CMF C17 H23 N O3
CDES *

Absolute stereochemistry.




CM 2

CRN 81-04-9
CMF C10 H8 O6 S2



RN 50372-92-4 CAPLUS
CN 8-Azabicyclo[3:2.1]octane-2-carboxylic acid, 3-(4-methoxyphenyl)-8-methyl-, methyl ester, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50372-95-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, 1-methylethyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/975,586




● HCl

RN 50372-96-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-phenyl-, methyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 50373-01-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-methoxyphenyl)-8-methyl-, methyl ester, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50373-02-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-methoxyphenyl)-8-methyl-, methyl ester, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

09/975,586


Absolute stereochemistry.



RN 50763-12-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-methoxyphenyl)-8-methyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50798-53-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-hydroxyphenyl)-8-methyl-, methyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 53898-66-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, 1-methylethyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

09/975,586


Absolute stereochemistry.



RN 53898-68-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-phenyl-, methyl ester,
(1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 53898-70-7 CAPLUS


CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl
ester, [1R-(exo,exo)]-, 1,5-naphthalenedisulfonate (2:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 50372-80-0

CMF C16 H21 N O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2



L13 ANSWER 517 OF 517 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1973:542793 CAPLUS

DOCUMENT NUMBER: 79:142793

TITLE: Compounds affecting the central nervous system. 4.
 3.beta.-Phenyltropane-3-carboxylic esters and analogs
 AUTHOR(S): Clarke, Robert L.; Daum, Sol J.; Gambino, Anthony J.;
 Aceto, Mario D.; Pearl, Jack; Levitt, Morton;
 Cumiskey, Wayne R.; Bogado, Eugenio F.

CORPORATE SOURCE: Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA

SOURCE: J. Med. Chem. (1973), 16(1), 1260-7

CODEN: JMCMAR

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Attachments of the benzene ring of cocaine directly to C-3 of the tropane moiety produced strongly enhanced stimulant activity. Thus, Me 3.beta.-(p-fluorophenyl)-1.alpha.H,5.alpha.H-tropane-2.beta.-carboxylate naphthalene-1,5-disulfonate (I) [43021-25-6] was 64 times as active orally as cocaine in stimulating local motor activity in mice (min. ED 1 mg/kg). I was 5 times as active as cocaine in preventing reserpine-induced eyelid ptosis in mice, and 20 times as active in reversing it. I had only about 15% of the intradermal local anesthetic activity of cocaine in guinea pigs. I was 22 times as active s.c. as cocaine in inhibiting norepinephrine uptake by rat brain, and apparently crossed the blood-brain barrier easily. The toxicity of I in mice was lower than that of cocaine. The enantiomers of the compds. were devoid of stimulative activity. The 3.beta.-aryltropanecarboxylic-esters were prep'd. by reaction of (-)-anhydroecgonine Me ester [43021-26-7] with the appropriate Grignard reagent; the epimers were sep'd. by chromatography or selective quaternization.

IT 43021-25-6P 50372-80-0P 50372-81-1P

50372-90-2P 50372-91-3P 50372-92-4P

50372-94-6P 50372-95-7P 50372-96-8P

50372-97-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and central nervous system activity of)

RN 43021-25-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, [1R-(exo,exo)]-, 1,5-naphthalenedisulfonate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 50370-56-4

CMF C16 H20 F N O2

CDES *

Absolute stereochemistry.


09/975,586



CM 2

CRN 81-04-9


CMF C10 H8 O6 S2



RN 50372-80-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 50372-81-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, hydrochloride, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/975,586



● HCl

RN 50372-90-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
methyl ester, hydrochloride, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 50372-91-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-methoxyphenyl)-8-methyl-,
methyl ester, [1R-(exo,exo)]-, 1,5-naphthalenedisulfonate (2:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 50763-12-7
CMF C17 H23 N O3
CDES *

Absolute stereochemistry.




09/975,586

CM 2

CRN 81-04-9


CMF C10 H8 O6 S2



RN 50372-92-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-methoxyphenyl)-8-methyl-, methyl ester, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50372-94-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, 1-methylethyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 50372-95-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, 1-methylethyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/975,586




● HCl

RN 50372-96-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-phenyl-, methyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 50372-97-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-, methyl ester, [1S-(exo,exo)]-, 1,5-naphthalenedisulfonate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 50370-59-7

CMF C16 H20 F N O2

Absolute stereochemistry. Rotation (+).


09/975,586



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




IT 50370-54-2P 50370-56-4P 50370-57-5P
50370-58-6P 50370-59-7P 50373-01-8P
50373-02-9P 50373-03-0P 50373-04-1P
50798-53-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 50370-54-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl
ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50370-56-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/975,586




RN 50370-57-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50370-58-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
1-methylethyl ester, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50370-59-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
methyl ester, [1S-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


09/975,586



RN 50373-01-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-methoxyphenyl)-8-methyl-, methyl ester, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50373-02-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-methoxyphenyl)-8-methyl-, methyl ester, [1R-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50373-03-0 CAPLUS


CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, [1S-(exo,exo)]-, 1,5-naphthalenedisulfonate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/975,586


CRN 50583-05-6
CMF C16 H21 N O2
CDES *

Absolute stereochemistry.




CM 2

CRN 81-04-9
CMF C10 H8 O6 S2



RN 50373-04-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(4-fluorophenyl)-8-methyl-,
methyl ester, [1S-(2-endo,3-exo)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 50798-53-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(3-hydroxyphenyl)-8-methyl-,
methyl ester, hydrochloride, [1R-(exo,exo)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/975,586



● HCl

=> d his

(FILE 'HOME' ENTERED AT 10:44:02 ON 21 MAY 2002)

FILE 'REGISTRY' ENTERED AT 10:44:14 ON 21 MAY 2002

L1 STRUCTURE UPLOADED
L2 49 S L1
L3 STRUCTURE UPLOADED
L4 29 S L3
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 STRUCTURE UPLOADED
L8 23 S L7
L9 0 S 3-4/NR AND 1-2/N AND 1-4/O
L10 1793550 S 3-4/NR AND 1-2/N AND 1-4/O
L11 19 S L7 SAM SUB=L10
L12 574 S L7 FULL

FILE 'CAPLUS' ENTERED AT 10:55:26 ON 21 MAY 2002

L13 517 S L12

FILE 'REGISTRY' ENTERED AT 10:56:26 ON 21 MAY 2002

L14 STRUCTURE UPLOADED
L15 23 S L14


FILE 'CAPLUS' ENTERED AT 10:59:29 ON 21 MAY 2002

=> d 17

L7 HAS NO ANSWERS

L7 STR

09/975,586



G1 [C1], [C2], [C3]

G2 H, Me

Structure attributes must be viewed using STN Express query preparation.